Aptose Biosciences has commenced dosing of participants in the Phase I/II APTIVATE clinical trial of tuspetinib (formerly HM43239) in acute myeloid leukemia (AML) patients.
The dose escalation, open-label, multicentre, and expansion Phase I/II APTIVATE study has been designed for evaluating the pharmacodynamics, tolerability, safety, and pharmacokinetics of HM43239 in relapsed or refractory (R/R) AML patients.
Go deeper with GlobalData
It will also confirm HM43239’s monotherapy activity through patient enrichment of specific, mutationally defined AML populations, including FLT3-mutant patients and TP53-mutant patients who were failed by a previous FLT3 inhibitor.
The APTIVATE expansion trial will also assess the PK parameters, tolerability, and safety of HM43239, along with venetoclax, in R/R AML patients.
The once daily oral agent tuspetinib has been designed to target SYK, JAK1/2, FLT3, and other kinases operative in AML, simultaneously.
As a monotherapy, tuspetinib was found to safely deliver several complete remissions and clinical responses across 40mg, 80mg, 120mg, and 160mg dose levels in AML patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThese patients were previously failed by chemotherapy, FLT3 inhibitors, BCL2 inhibitors, hematopoietic stem cell transplants, and hypomethylating agents.
Aptose Biosciences chairman, president, and CEO William Rice said: “We are pleased to have dosing underway in our APTIVATE clinical trial of tuspetinib in a very ill R/R AML population.
“Tuspetinib has demonstrated noteworthy safety and mutation agnostic potency across a spectrum of AML patients with a diversity of adverse mutations, further distinguishing it from competing compounds and targeting a much larger AML population.
“This breadth of activity, along with its significant safety profile, has allowed us to define a precise clinical and commercial plan for tuspetinib in multiple lines of therapy, including its use in doublet and triplet combinations, as well as maintenance therapy.”
The company also stated that an R/R AML patient receiving 40mg tuspetinib orally once a day in the dose exploration trial has achieved another clinical response.
